Neonatal SEPSIS Clinical Trial
Official title:
Prognostic Value of Red Cell Distribution Width (RDW) in Neonatal Sepsis in Patients Admitted at Assiut University Children Hospital.
1. Evaluate the relationship of RDW and severity and mortality in patients with neonatal
sepsis .
2. Using RDW as a simple, inexpensive, applicable and rapid test to detect prognosis of
neonatal sepsis .
Sepsis is defined as a life-threatening condition caused by a dysregulated host response to
infection. Sepsis is responsible for approximately 45% of neonatal emergencies and is a
leading cause of neonatal mortality and morbidity, accounting for 14% of deaths in that age
group.
The early symptoms and signs of neonatal sepsis are usually mild and nonspecific but can
rapidly progress to septic shock, disseminated intravascular coagulation(DIC), and death. It
is therefore of paramount importance to find a tool for prediction of infants who are more
likely to experience a worse clinical outcome so that closer monitoring and more aggressive
treatment would be offered to them.
Early-onset sepsis (EOS) is usually due to transplacental, ascending, or intrapartum
transmission in the perinatal period shortly before or during birth, up to postnatal (PN) 7
days. Late-onset sepsis (LOS) is acquired by horizontal transmission in the home, hospital,
or in the community after PN day.
Timely diagnosis and prompt institution of antimicrobial therapy are essential in order to
mitigate the high case fatality and to avert morbidity associated with late-onset neonatal
sepsis. In the latest years, biochemical markers are important in research areas in neonatal
infections. Inflammatory cascade as response to an infection comprise many elevated markers,
frequently used for diagnosis and monitoring of sepsis.
Numerous molecules have been studied as potentially useful prognostic markers in neonatal
sepsis. These include C-reactive protein (CRP), procalcitonin, IL-6, IL-8, CD64, and soluble
E- selectin.
The red cell distribution width (RDW) is a marker, which has been studied in neonatal sepsis.
The RDW is a measure of variability of red blood cells in size (anisocytosis) and is
routinely evaluated as a part of complete blood count. The RDW may be elevated in conditions
of ineffective production, or increased destruction of red blood cells, which commonly occur
in inflammatory or infectious situations.
Red cell distribution width has been classically used as a screening index for iron
deficiency anemia. However, a growing body of evidence indicates that this simple marker can
have a role in predicting adverse outcome in sepsis as well as in diverse clinical
situations, including coronary artery disease, heart failure,acute pancreatitis, malignancy,
infective endocarditis, peritoneal dialysis, and in critically ill children in general.
The pathophysiology of the elevation of RDW in these patients is not well known, but it has
been reported that elevated RDW is associated with inflammatory markers such as C-reactive
protein (CRP), erythrocyte sedimentation rate, interleukin-6 and tumor necrosis factor-alpha.
Proinflammatory cytokines of sepsis have been shown to suppress the maturation of red blood
cells (RBC) and decrease the half-life of RBCs, resulting in the elevation of RDW values Most
previous studies investigating the prognostic value of RDW were conducted on adult patients,
and similar studies in neonatal sepsis are rare and small. The objective of the present
research is to investigate the prognostic role of this routinely available marker in full
term neonates with sepsis and to compare it with other traditional prognostic biomarkers.
The prognostic potential of RDW is of particular interest because it is routinely included in
the automated complete blood count (CBC) analyses in hospitalized patients and thus available
and no additional cost for clinicians.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05692128 -
Frequency and Severity of Thrombocytopenia in Neonatal Sepsis
|
||
Completed |
NCT00942084 -
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
|
Phase 1 | |
Completed |
NCT06002295 -
A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns
|
Phase 2 | |
Not yet recruiting |
NCT05114057 -
Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI
|
N/A | |
Recruiting |
NCT04528251 -
Comparison of the Effectiveness of Two Different Antibiotic Regimens of the Treatment of Pregnant Women With Preterm Rupture of Membranes
|
||
Active, not recruiting |
NCT03871491 -
Azithromycin-Prevention in Labor Use Study (A-PLUS)
|
Phase 3 | |
Completed |
NCT03746743 -
Severity Index of Neonatal Septicemia Using Score for Neonatal Acute Physiology (SNAP) II
|
||
Completed |
NCT02386592 -
Prevention of Nosocomial Bacteremia Among Zambian Neonates
|
N/A | |
Not yet recruiting |
NCT06113653 -
Outcomes and Predictors of Mortality Among Preterm Infants With Neonatal Sepsis
|
||
Completed |
NCT03199547 -
Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death
|
Phase 3 | |
Completed |
NCT02147327 -
Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities
|
N/A | |
Completed |
NCT01005589 -
CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis
|
N/A | |
Completed |
NCT00866567 -
Defects in Opsonophagocytosis in Premature Infants
|
N/A | |
Completed |
NCT02281890 -
Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database
|
N/A | |
Suspended |
NCT05156333 -
Probiotics and GBS Colonization in Pregnancy
|
N/A | |
Recruiting |
NCT05127070 -
Evaluating the NeoTree in Malawi and Zimbabwe
|
||
Completed |
NCT03755635 -
Neonatal Sepsis at Neonatal Intensive Care Units in Ghana
|
N/A | |
Completed |
NCT03247920 -
Reduction of Intravenous Antibiotics In Neonates
|
Phase 4 | |
Completed |
NCT03295162 -
Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis
|
Phase 1/Phase 2 | |
Completed |
NCT02954926 -
Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
|
Phase 3 |